Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Takeda Pharmaceutical Company

Tracked across 23 events · 299 articles · First seen Feb 19, 2026 · Last active Sep 22, 2026

Sentiment
24
Attention
6
Events
23
Relationships
4
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 70
Tech
Impact: Takeda Pharmaceutical Company presented positive additional results from two pivotal studies for its drug oveporexton, which could redefine the standard of care for narcolepsy type 1, potentially increasing its market share and revenue in the pharmaceutical industry. Its shares were down 2.18% on the day of the announcement, but the long-term outlook is positive if the drug is approved.
Jun 15, 2026 · 6 articles
6 60
Business
Impact: Takeda Pharmaceutical Company is partnering with Insilico Medicine to integrate AI into its drug discovery process, aiming to accelerate the identification of novel drug candidates and transition to an AI-native discovery model. This collaboration grants Takeda exclusive worldwide rights to develop and commercialize therapeutics from this partnership.
Jul 02, 2026 · 8 articles
4 80
Regulatory
Impact: Takeda is the developer and manufacturer of QDENGA, the first dengue vaccine approved in India. This approval expands its market to India, the country with the highest dengue burden, and strengthens its global vaccine portfolio.
Jul 20, 2026 · 93 articles
6 80
Regulatory
Impact: Takeda developed and received FDA approval for Orzeyful, its first-in-class orexin agonist for narcolepsy type 1. This approval strengthens its pipeline and market position, though the company expects no significant impact on its fiscal 2027 forecast.
Aug 05, 2026 · 21 articles
4 80
Regulatory
Impact: Takeda gains exclusive commercialization rights to Mimrylo, a potential blockbuster with projected peak sales of $1-2 billion, helping offset patent losses on Entyvio. The approval strengthens its hematology portfolio and supports earnings growth.
Aug 28, 2026 · 6 articles
3 20
Business
Abbott Laboratories and Takeda Pharmaceutical Company announced on September 18, 2026 an exclusive distribution agreement under which Dr. Reddy's will promote and distribute Takeda's dengue vaccine QDENGA across India's private market for pediatric and adult…
Impact: Developer and legal owner of QDENGA, securing a strong Indian distribution partner for the private market while retaining public-market and brand oversight rights.
Sep 18, 2026 · 20 articles
4 0
Business
Impact: Takeda Pharmaceutical Company terminated its collaboration agreement with Denali Therapeutics for DNL593 due to strategic considerations, not related to efficacy or safety data.
Apr 03, 2026 · 7 articles
6 60
Tech
Impact: Takeda Pharmaceutical Company is co-developing IBI363 with Innovent Biologics and will exclusively commercialize it globally outside the U.S. and greater China. The positive clinical results for IBI363 strengthen Takeda's oncology portfolio and future revenue potential.
May 21, 2026 · 9 articles
2 30
Tech
Impact: Takeda is a consortium member. The study's findings could influence its trial designs for neurodegenerative diseases.
Aug 18, 2026 · 6 articles
2 20
Business
On September 8, 2026, AnBogen Therapeutics announced that its Board of Directors authorized a share repurchase program of up to $300 million of its outstanding common stock. The company plans to fund the repurchases using…
Impact: Takeda is a collaboration partner whose royalty and milestone payments, including a $200 million opt-out and $75 million milestone, help fund the repurchase. This reflects ongoing successful partnership and financial inflows to Protagonist.
Sep 08, 2026 · 7 articles
4 -40
Business
Impact: Takeda Pharmaceutical's stock declined, showing a negative performance.
May 21, 2026 · 40 articles
4 20
Regulatory
Impact: Takeda is the Japanese laboratory that produces another dengue vaccine, which continues to be used without problems in Brazil, potentially seeing increased demand due to the suspension of the local vaccine.
Jun 08, 2026 · 7 articles
2 0
Business
Impact: Takeda Pharmaceutical Company is the licensee for rusfertide, another peptide discovered by AnBogen Therapeutics.
May 28, 2026 · 6 articles
2 40
Business
Impact: Collaboration partner; contributes to Insilico's revenue growth, but no direct impact from index inclusion.
Jul 20, 2026 · 6 articles
6 10
Tech
Impact: Takeda Pharmaceutical Company Limited is a funding partner for the project, supporting the research into Alzheimer s disease biomarkers.
Feb 19, 2026 · 6 articles
2 10
Tech
Impact: Takeda Pharmaceutical Company is a sponsor of World Hemophilia Day 2026, supporting the World Federation of Hemophilia's efforts.
Apr 17, 2026 · 6 articles
1 0
Business
Impact: Takeda Pharmaceutical Company is licensed to develop and commercialize rusfertide, another peptide therapeutic discovered by AnBogen Therapeutics.
Jun 16, 2026 · 6 articles
3 0
Business
Impact: Late-stage programs including mezagitamab and externalized assets included in acquired portfolio.
Jul 14, 2026 · 6 articles
4 5
Tech
Insilico Medicine announced on September 9-10, 2026 that it has dosed the first patient with Rentosertib (ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial for idiopathic pulmonary fibrosis (IPF), at United Medical College…
Impact: Takeda Pharmaceutical Company is mentioned as a partner in Insilico's out-licensing and co-development deals. The event has minimal direct impact on Takeda.
Sep 10, 2026 · 6 articles
2 0
Business
Impact: Penny Carlson previously served as Vice President and Head of Global Clinical Development Operations at Takeda Pharmaceutical Company, indicating her extensive experience in the biopharmaceutical industry.
Jun 08, 2026 · 6 articles
2 5
Business
Iambic Therapeutics, a San Diego-based drug developer backed by Nvidia and the Qatar Investment Authority, filed for a US initial public offering on Monday, September 21, 2026, aiming to list on the Nasdaq under the…
Impact: Listed as an existing partnership partner of Iambic, with no new action in this event.
Sep 21, 2026 · 6 articles
0 0
Business
Impact: Takeda is the licensee of rusfertide, which is under FDA priority review. No direct impact from this event.
Aug 04, 2026 · 9 articles
0 0
Business
Impact: Takeda is a partner of Ascentage Pharma, but this event does not directly involve Takeda.
Jul 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Takeda Pharmaceutical Company live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.